Evidence map›Paper›PMID 37933788›Full record

ArticleJournal of clinical pharmacology2024

Population Pharmacokinetics of Caffeine in Neonates with Congenital Heart Disease and Associations with Acute Kidney Injury.

Elizabeth J Thompson, Kanecia O Zimmerman, Daniel Gonzalez, Henry P Foote, Sangah Park, Kevin D Hill, Jillian H Hurst, Chi D Hornik, Reid C Chamberlain, Rasheed A Gbadegesin and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of clinical pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Caffeine for the prevention of acute kidney injury in neonates: a systematic review and meta-analysis.Journal of perinatology : official journal of the California Perinatal Association · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Elizabeth J ThompsonDepartment of Pediatrics, Duke University Hospital, Durham, NC, USA.ORCID 0000-0001-5079-9920
Kanecia O ZimmermanDepartment of Pediatrics, Duke University Hospital, Durham, NC, USA.
Daniel GonzalezDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.ORCID 0000-0001-5522-5686
Henry P FooteDepartment of Pediatrics, Duke University Hospital, Durham, NC, USA.
Sangah ParkDuke University, Durham, NC, USA.
Kevin D HillDepartment of Pediatrics, Duke University Hospital, Durham, NC, USA.
Jillian H HurstDepartment of Pediatrics, Duke University Hospital, Durham, NC, USA.
Chi D HornikDepartment of Pediatrics, Duke University Hospital, Durham, NC, USA.
Reid C ChamberlainDepartment of Pediatrics, Duke University Hospital, Durham, NC, USA.
Rasheed A GbadegesinDepartment of Pediatrics, Duke University Hospital, Durham, NC, USA.
Christoph P HornikDepartment of Pediatrics, Duke University Hospital, Durham, NC, USA.
Clinical Research Institute · USDuke University Hospital · USUniversity of North Carolina at Chapel Hill · USDuke University · US

Funding

UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program-Evaluation SupplementT32GM086330 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER, Daniel Gonzalez · 2011 to 2026
$8.5M
Global Pediatric Clinical Trials NetworkU18FD006298 · FDA · DUKE UNIVERSITY · PI COHEN-WOLKOWIEZ, MICHAEL, HORNIK, CHRISTOPH · 2017 to 2021
$5.5M
Application of Physiologically-Based Pharmacokinetic Modeling to Characterize Drug-Drug Interactions in InfantsR01HD102949 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Daniel Gonzalez · 2021 to 2026
$3.0M
Unified Program for Therapeutics in Children (UPTiC)T32HD094671 · NICHD · DUKE UNIVERSITY · PI Ian J Davis, Kanecia Obie Zimmerman · 2019 to 2026
$2.9M
Physiologically-Based Pharmacokinetic Modeling to Guide Drug Dosing in Children with ObesityR01HD096435 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUMOND, JULIE BRUMER · 2018 to 2022
$2.0M
Duke-UNC Collaborative Pediatric Clinical Pharmacology Postdoctoral Training ProgramT32HD104576 · NICHD · DUKE UNIVERSITY · PI BROUWER, KIM L.R., GONZALEZ, DANIEL · 2021 to 2025
$962k
Clinical and host microbiome features in the development of acute otitis mediaK01AI173398 · NIAID · DUKE UNIVERSITY · PI Jillian Heyward Hurst · 2023 to 2026
$509k
FDA HHS U18 FD006298NIAID NIH HHS K01 AI173398NICHD NIH HHS L40 HD109869NICHD NIH HHS R01 HD096435NICHD NIH HHS R01 HD102949NICHD NIH HHS T32 HD094671NICHD NIH HHS T32 HD104576NIGMS NIH HHS T32 GM086330
6 · The paper itself

Abstract

Cardiac surgery-associated acute kidney injury (CS-AKI) occurs in approximately 65% of neonates undergoing cardiac surgery on cardiopulmonary bypass and contributes to morbidity and mortality. Caffeine may reduce CS-AKI by counteracting adenosine receptor upregulation after bypass, but pharmacokinetics (PK) in this population are unknown. The goal of our analysis is to address knowledge gaps in age-, disease-, and bypass-related effects on caffeine disposition and explore preliminary associations between caffeine exposure and CS-AKI using population PK modeling techniques and an opportunistic, electronic health record-integrated trial design. We prospectively enrolled neonates receiving preoperative caffeine per standard of care and collected PK samples. We retrospectively identified neonates without caffeine exposure undergoing surgery on bypass as a control cohort. We followed US Food and Drug Administration guidance for population PK model development using NONMEM. Effects of clinical covariates on PK parameters were evaluated. We simulated perioperative exposures and used multivariable logistic regression to evaluate the association between caffeine exposure and CS-AKI. Twenty-seven neonates were included in model development. A 1-compartment model with bypass time as a covariate on clearance and volume of distribution best fit the data. Twenty-three neonates with caffeine exposure and 109 controls were included in the exposure-response analysis. Over half of neonates developed CS-AKI. On multivariable analysis, there were no significant differences between CS-AKI with and without caffeine exposure. Neonates with single-ventricle heart disease without CS-AKI had consistently higher simulated caffeine exposures. Our results highlight areas for further study to better understand disease- and bypass-specific effects on drug disposition and identify populations where caffeine may be beneficial.

Indexed as

Acute Kidney InjuryCardiac Surgical ProceduresHeart Defects, CongenitalCaffeineCardiopulmonary BypassHumansInfant, NewbornRetrospective StudiesRisk FactorsCaffeineacute kidney injurycongenital heart diseasepediatricspopulation pharmacokinetics

Identifiers

PMID37933788
PMCPMC10898646
OpenAlexW4388455181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.